Cellular and molecular immunology, 2003. ,
Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinase, Am j cancer res, vol.2, issue.4, pp.446-458, 2012. ,
Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register, Annals of the Rheumatic Diseases, vol.68, issue.5, pp.648-655, 2009. ,
DOI : 10.1136/ard.2007.085852
Tumour necrosis factor and cancer, Nature Reviews Cancer, vol.265, issue.5, pp.361-371, 2009. ,
DOI : 10.1038/nature01322
Ulcerative colitis in smokers, non-smokers and ex-smokers, World Journal of Gastroenterology, vol.17, issue.22, pp.2740-2747, 2011. ,
DOI : 10.3748/wjg.v17.i22.2740
Production of functional chimaeric mouse/human antibody, Nature, vol.103, issue.5995, pp.312-643, 1984. ,
DOI : 10.1128/MCB.2.9.1033
Maintenance of infliximab treatment in ankylosing spondylitis: Results of a one-year randomized controlled trial comparing systematic versus on-demand treatment, Arthritis & Rheumatism, vol.54, issue.1, pp.88-97, 2008. ,
DOI : 10.1016/S1521-6942(02)90245-7
URL : https://hal.archives-ouvertes.fr/hal-00496246
True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin ???, Annals of the Rheumatic Diseases, vol.63, issue.10, pp.1344-1346, 2004. ,
DOI : 10.1136/ard.2003.014878
To switch or not to switch after a poor response to a TNF?? blocker? It is not only a matter of ACR20 OR ACR50, Autoimmunity Reviews, vol.11, issue.8, pp.558-562, 2012. ,
DOI : 10.1016/j.autrev.2011.10.012
The Clinical Genetics of Psoriasis, Current Genomics, vol.6, issue.1, pp.51-60, 2005. ,
DOI : 10.2174/1389202053202157
Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship?, J Rheumatol, vol.33, issue.5, pp.1014-1017, 2006. ,
Immunologie (5ème édition) De la biologie à la clinique. Flammarion Médecine-sciences, p.416, 2008. ,
The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis, Clin Exp Rheumatol, vol.23, issue.6, pp.795-800, 2005. ,
Item 118, 2009. ,
Hepato-Gastro-Entérologie, pp.71-87 ,
Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.65, issue.6, pp.746-752, 2006. ,
DOI : 10.1136/ard.2005.045062
Réaction inflammatoire. Immunologie 4 ème édition, Genetet N, 2002. ,
Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management, The Lancet Infectious Diseases, vol.3, issue.3, pp.148-155, 2003. ,
DOI : 10.1016/S1473-3099(03)00545-0
IMMUNOLOGIE, le cours de janis Kuby. Dunod, pp.371-393, 2003. ,
Small-molecule inhibition of TNF-alpha, Science, issue.5750, pp.310-1022, 2005. ,
Efficacité de l'infliximab dans le traitement d'un psoriasis pustuleux généralisé induit par l'hydroxychloroquine. Annales de dermatologie et de vénérologie, pp.138-206, 2011. ,
DOI : 10.1016/j.annder.2011.10.201
Heberden Oration, 1969. Rheumatoid arthritis--nature or nurture?, Annals of the Rheumatic Diseases, vol.29, issue.4, pp.357-379, 1970. ,
DOI : 10.1136/ard.29.4.357
Risques des médicaments anti-inflammatoires et immunosuppresseurs au cours de la grossesse. La Revue de médecine interne, pp.31-35, 2011. ,
Mouse/human chimeric monoclonal antibody in man: kinetics and immune response., Proceedings of the National Academy of Sciences, vol.86, issue.11, pp.86-4220, 1989. ,
DOI : 10.1073/pnas.86.11.4220
Hepatosplenic T Cell Lymphoma Associated With Infliximab Use in Young Patients Treated for Inflammatory Bowel Disease, Journal of Pediatric Gastroenterology and Nutrition, vol.44, issue.2, pp.265-267, 2007. ,
DOI : 10.1097/MPG.0b013e31802f6424
Placental Transfer of Anti???Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel Disease, Clinical Gastroenterology and Hepatology, vol.11, issue.3, pp.286-292, 2013. ,
DOI : 10.1016/j.cgh.2012.11.011
Effects of an Anti-TNF-? Monoclonal Antibody, Administered Throughout Pregnancy and Lactation, on the Development of the Macaque Immune System, American Journal of Reproductive Immunology, vol.28, issue.2, pp.138-149, 2007. ,
DOI : 10.1016/j.cyto.2005.07.003
Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis, Annals of the Rheumatic Diseases, vol.62, issue.1, 2003. ,
DOI : 10.1136/ard.62.1.74
Golimumab, mAbs, vol.66, issue.5, pp.422-431, 2009. ,
DOI : 10.2165/00003495-200969050-00007
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial, The Lancet, vol.382, issue.9894, p.381, 2013. ,
DOI : 10.1016/S0140-6736(13)60594-2
Adalimumab in the treatment of arthritis, Therapeutics and Clinical Risk Management, vol.3, issue.1, pp.133-148, 2007. ,
DOI : 10.2147/tcrm.2007.3.1.133
atlas du rhumatisme psoriasique, p.122, 2009. ,
-[4-[2-Ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a Potent and Orally Active Anti-Rheumatoid Arthritis Agent, Journal of Medicinal Chemistry, vol.48, issue.19, pp.5966-5979, 2005. ,
DOI : 10.1021/jm050165o
KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase, European Journal of Pharmacology, vol.632, issue.1-3, pp.1-3, 2010. ,
DOI : 10.1016/j.ejphar.2010.01.011
Childhood Psoriasis: A Clinical Review of 1262 Cases, Pediatric Dermatology, vol.20, issue.3, pp.188-198, 2001. ,
DOI : 10.1111/j.1365-4362.1981.tb00423.x
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains., Proceedings of the National Academy of Sciences, vol.81, issue.21, 1984. ,
DOI : 10.1073/pnas.81.21.6851
URL : http://www.pnas.org/content/81/21/6851.full.pdf
Treatment of respiratory complications in recalcitrant relapsing polychondritis with infliximab, Rheumatology, vol.42, issue.9, pp.1117-1118, 2003. ,
DOI : 10.1093/rheumatology/keg280
Tumor necrosis alpha-blocking agent (etanercept): a triple blind randomized controlled trial of its use in treatment of sciatica, 2010. ,
Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab, Clin, 2011. ,
Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis, Journal of Immunological Methods, vol.348, issue.1-2, pp.1-2, 2009. ,
DOI : 10.1016/j.jim.2009.06.009
Clinical development of onercept, a tumor necrosis factor binding protein, in psoriasis, Current Medical Research and Opinion, vol.26, issue.10, pp.2287-2300, 2010. ,
DOI : 10.1185/03007995.2010.507492
Adalimumab maintenance therapy for Crohn???s disease with intolerance or lost response to infliximab: an open-label study, Alimentary Pharmacology & Therapeutics, vol.100, issue.Suppl., 2007. ,
DOI : 10.1136/gut.40.4.443
A comprehensive review of the genetics of juvenile idiopathic arthritis, Pediatric Rheumatology, vol.6, issue.1, p.16, 2008. ,
DOI : 10.1186/1546-0096-6-11
Certolizumab pegol: new drug As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors, Prescrire Int, vol.18, issue.101, pp.108-110, 2009. ,
Juvenile idiopathic arthritis. The Lancet, 2007. ,
The prevalence of psoriasis in the world, Journal of the European Academy of Dermatology and Venereology, vol.25, issue.4, pp.16-17, 2001. ,
DOI : 10.1111/j.1440-0960.1984.tb00618.x
Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and metaanalysis, Clin Exp Rheumatol, vol.29, issue.1, pp.96-103, 2011. ,
Humanization of murine monoclonal antibodies through variable domain resurfacing., Proceedings of the National Academy of Sciences, vol.91, issue.3, pp.969-973, 1994. ,
DOI : 10.1073/pnas.91.3.969
Etanercept for active Crohn's disease: A randomized, double-blind, 2001. ,
CDP571, a humanised monoclonal antibody to tumour necrosis factor ??, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial, Gut, vol.53, issue.10, pp.53-1485, 2004. ,
DOI : 10.1136/gut.2003.035253
Polyarthrite rhumatoïde de l'adulte, conception actuelle, John Libbey Eurotext, p.298, 2003. ,
Psoriasis, New England Journal of Medicine, vol.352, issue.18, pp.1899-1912, 2005. ,
DOI : 10.1056/NEJMra041320
Microbiote intestinal et MICI, Gastroent??rologie Clinique et Biologique, vol.34, issue.4, pp.48-55, 2010. ,
DOI : 10.1016/S0399-8320(10)70007-5
Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis, 2006. ,
Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor ??, mAbs, vol.54, issue.4, 2010. ,
DOI : 10.1186/ar1028
Anticorps monoclonaux à usage thérapeutique : un peu d'histoire, 2005. ,
Risk of Lymphoma Associated With Combination Anti???Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis, Clinical Gastroenterology and Hepatology, vol.7, issue.8, pp.874-881, 2009. ,
DOI : 10.1016/j.cgh.2009.01.004
RWJ- 67657, a potent, 1999. ,
Tumour necrosis factor antagonists: structure, function, and tuberculosis risks, The Lancet Infectious Diseases, vol.8, issue.10, pp.601-611, 2008. ,
DOI : 10.1016/S1473-3099(08)70227-5
Immunopathologie et réactions inflammatoires, p.310, 2003. ,
Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study, Alimentary Pharmacology and Therapeutics, vol.13, issue.4, pp.11-12, 2004. ,
DOI : 10.1016/S0002-9270(02)05259-0
TNF?? blockade in human diseases: Mechanisms and future directions, Clinical Immunology, vol.126, issue.2, pp.121-136, 2008. ,
DOI : 10.1016/j.clim.2007.08.013
URL : http://europepmc.org/articles/pmc2291518?pdf=render
(page consultée en février 2013b) Notice HUMIRA®. Disponible sur <http://www.ema.europa.eu/docs/fr_FR/document_library/EPAR_- Product_Information/human/000481/WC500050870.pdf> ? ema.europa.eu (page consultée en mars 2013c). Notice SIMPONI®. Disponible sur <http Disponible sur <http ,
net/consor4.01/www/cgi- bin/Disease_Search.php?lng=FR&data_id=806&Disease_Disease_Search_diseaseGr oup=Takayasu> ? HAS-santé.fr (page consultée en janvier 2013a) Arthrite juvénile idiopathique ,
09/ald_31_pnds_arthrite_juvenile_web.pdf> ? HAS-santé.fr (page consultée en février 2013b) Avis de la commission de transparence du 3 octobre 2012 concernant REMICADE®. Disponible sur <http, 2009. ,